(Q34347908)

1 August 2017

1 reference

title

In vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models? (English)

1 reference

1 August 2017

1 reference

MacGowan A

1

1 reference

1 August 2017

Rogers C

series ordinal

2

1 reference

1 August 2017

Bowker K

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

Clinical Infectious Diseases

1 August 2017

published in

1 reference

1 August 2017

volume

33 Suppl 3

1 reference

1 August 2017

page(s)

S214-20

1 reference

In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa

1 August 2017

cites work

1 reference

Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model

21 January 2018

1 reference

Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection

21 January 2018

1 reference

Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin

21 January 2018

1 reference

The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model.

21 January 2018

1 reference

Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model

21 January 2018

1 reference

Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G.

21 January 2018

1 reference

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

21 January 2018

1 reference

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

21 January 2018

1 reference

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

21 January 2018

1 reference

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/321850

1 reference

1 August 2017

1 reference